RESUMO
OBJECTIVE: To evaluate the therapeutic effects of a (32)P-patch in the treatment of a murine melanoma. MATERIALS AND METHODS: Thirty male C57BL6 mice were divided into two groups: treated and control. Superficial tumors were induced in both groups by injecting B16F1 melanoma at about 10 cells/mouse subcutaneously. Tumors developed 10-15 days after transplantation and the (32)P-patch was applied on palpable tumors of the treated group. Tumor growth was followed up in both groups by measuring tumor size with a caliper. After the follow-up period, the animals were killed and tumor samples of the treated and control groups were collected for histological study by preparing paraffin sections stained with hematoxylin-eosin. RESULTS: The (32)P-patch showed the absence of radioactivity leakage in vitro and the homogeneous distribution of the radionuclide. The skin surface at the application site of the (32)P-patch appeared hairless, and erythema developed, but reversed to normal after a few days in the treated group. Control of tumor growth was achieved in the treated group compared with the control group, although complete remission did not occur. CONCLUSION: The (32)P-patch tested for the treatment of a murine melanoma model showed its efficacy, as tumor growth was retarded after application of the patch Nevertheless, adjustment of some therapeutic parameters and/or combining the patch with other treatment modalities may be necessary to achieve complete regression. The P-patch represents a powerful tool to individualize the treatment of melanoma.
Assuntos
Melanoma/radioterapia , Radioisótopos de Fósforo/administração & dosagem , Radioisótopos de Fósforo/uso terapêutico , Neoplasias Cutâneas/radioterapia , Administração Tópica , Animais , Braquiterapia , Linhagem Celular Tumoral , Fracionamento da Dose de Radiação , Masculino , Melanoma/patologia , Camundongos , Traçadores Radioativos , Neoplasias Cutâneas/patologia , Carga TumoralRESUMO
The purpose of this study was to design and evaluate a 32P patch for brachytherapy of skin diseases. We employed Phosphoric-32P-acid and Chromic 32P-phosphate in combination with natural rubber or silicone to produce the patches. Stability studies in vitro to evaluate the leakage of radioactivity, autoradiographic studies to evaluate homogeneity and shielding, as well as therapeutic efficacy in an animal model of skin cancer of the selected 32P patch were performed. The 32P-silicone-patch demonstrated its safety for external application. Tumor growth was arrest and complete regressions of tumors were seen in some other cases with 40 Gy applied in a single-dose scheme. In conclusion, the 32P-silicone-patch is easy to prepare and use in the treatment of skin diseases.
Assuntos
Braquiterapia/métodos , Radioisótopos de Fósforo/administração & dosagem , Neoplasias Cutâneas/radioterapia , Animais , Compostos de Cromo/administração & dosagem , Compostos de Cromo/química , Sistemas de Liberação de Medicamentos/métodos , Feminino , Histocitoquímica , Camundongos , Camundongos Endogâmicos SENCAR , Fosfatos/administração & dosagem , Fosfatos/química , Ácidos Fosfóricos/administração & dosagem , Ácidos Fosfóricos/química , Radioisótopos de Fósforo/química , Planejamento da Radioterapia Assistida por Computador , Distribuição Aleatória , Borracha/administração & dosagem , Borracha/química , Silicones/administração & dosagem , Silicones/químicaRESUMO
With the purpose studying the effectivity of an intratumoral single dose of chromic [(32)P] phosphate with great particles for the treatment of solid tumors, studies of biolimination, biodistribution and therapeutic action were carried out. Only for comparative purpose, similar studies were undertaken using a solution of sodium [(32)P] orthophosphategelatine. The results show that when sodium [(32)P] orthophosphategelatine is used, the percentage of total elimination is (85.90+8,70) per cent with a higler percentage in urine (64.50+13.70) per cent than in faeces (21.40+4.50) per cent. In biodistribution studies, the greater percentage is found in bone (15.54+2.21) per cent while only a (2.51+0.39) per cent remains in the tumor. When great particles chromic [(32)P] phosphate was intratumorally injected, we determined that the total elimination is equal (36.28+6.27) per cent, finding a higler amount in faeces (29.44+5.26) per cent than in urine (6.84+2.21) per cent. Biodistribution studies demonstrated that (49.82+5.41) per cent remains in the tumor and (9.63+4.89) per cent of the injected activity is found in the liver. On the other hand, when therapeutic action was evoluted, we observed that the percentage of tumor regression (P.T.R) is 52.0 per cent for the tumors injected with chromic [(32)P] phosphate and 0.0 per cent for those injected with sodium [(32)P] orthophosphate-gelatine. These results show that the great particles colloid of chromic [(32)P] phosphate is not safe enough for the tratment of solid tumors, since it is mobilezed from the injection point, delivering a high dose to the whole organism.
Assuntos
Animais , Ratos , Feminino , Adenocarcinoma/radioterapia , Compostos de Cromo/uso terapêutico , Neoplasias Mamárias Experimentais/radioterapia , Fosfatos/uso terapêutico , Radioisótopos de Fósforo/uso terapêutico , Sódio/uso terapêutico , Compostos de Cromo/administração & dosagem , Compostos de Cromo/farmacocinética , Coloides , Fezes/química , Injeções , Fosfatos/administração & dosagem , Fosfatos/farmacocinética , Radioisótopos de Fósforo/administração & dosagem , Radioisótopos de Fósforo/farmacocinética , Ratos Sprague-Dawley , Indução de Remissão , Sódio/administração & dosagem , Sódio/farmacocinética , Resultado do Tratamento , Urina/químicaRESUMO
With the purpose studying the effectivity of an intratumoral single dose of chromic [(32)P] phosphate with great particles for the treatment of solid tumors, studies of biolimination, biodistribution and therapeutic action were carried out. Only for comparative purpose, similar studies were undertaken using a solution of sodium [(32)P] orthophosphategelatine. The results show that when sodium [(32)P] orthophosphategelatine is used, the percentage of total elimination is (85.90+8,70) per cent with a higler percentage in urine (64.50+13.70) per cent than in faeces (21.40+4.50) per cent. In biodistribution studies, the greater percentage is found in bone (15.54+2.21) per cent while only a (2.51+0.39) per cent remains in the tumor. When great particles chromic [(32)P] phosphate was intratumorally injected, we determined that the total elimination is equal (36.28+6.27) per cent, finding a higler amount in faeces (29.44+5.26) per cent than in urine (6.84+2.21) per cent. Biodistribution studies demonstrated that (49.82+5.41) per cent remains in the tumor and (9.63+4.89) per cent of the injected activity is found in the liver. On the other hand, when therapeutic action was evoluted, we observed that the percentage of tumor regression (P.T.R) is 52.0 per cent for the tumors injected with chromic [(32)P] phosphate and 0.0 per cent for those injected with sodium [(32)P] orthophosphate-gelatine. These results show that the great particles colloid of chromic [(32)P] phosphate is not safe enough for the tratment of solid tumors, since it is mobilezed from the injection point, delivering a high dose to the whole organism. (AU)